CI

At a glance

ClinicalIndex Comparison Record
Phase 1Unknown· 18 target
Drug / intervention
Sapropterin dihydrochloride tabletsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05299203
NCT05299203Phase 1Unknown

Phase Ia/Ib Clinical Trial of Sapropterin Dihydrochloride Tablets in the Prevention and Treatment of Radiation-induced Skin Reactions in Intensity Modulated Radiotherapy for Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)

West China Hospital·interventional·Posted Mar 28, 2022·Updated Mar 28, 2022

In Brief

A Phase 1 clinical trial evaluating Sapropterin dihydrochloride tablets for Head and Neck Squamous Cell Carcinoma. Targeting 18 participants.

Detailed Summary

Head and neck squamous cell carcinoma (include nasopharyngeal carcinoma) is one of the most common malignant tumor in China, and radiotherapy is the main treatment method. Radiation-induced dermatitis is one of the most common complications of head and neck squamous cell carcinoma patients during radiotherapy. Severe radiation dermatitis will cause secondary infection, severe pain, and even lead to the interruption of radiotherapy. On the one hand, it will affect the efficacy of tumor treatment, which may affect the long-term survival of patients, and on the other hand, it will also seriously affect the quality of life of patients. Tetrahydrobiopterin(BH4), also known as sapropterin, has been shown not only to reduce the severity of acute radiation dermatitis but also to enhance the repair of skin injury in animal experiments. It may be a new approach and method for the prevention and treatment of radiation-induced dermatitis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

Phase 1UnknownOverdue
2023202420252026
First PostedMar 28, 2022
Enrollment StartMay 1, 2022
Primary CompletionDec 1, 2022
Study CompletionMay 1, 2023
TodayJul 1, 2026
Enrollment to primary: 7 monthsPosted 4.3 years ago

Interventions

Sapropterin dihydrochloride tabletsdrug

dose escalation phase (BH4) aqueous solution is sprayed onto the skin of all radiotherapy areas, 3 times a day until two weeks after the end of radiotherapy.